Zelboraf Package Insert

HIGHLIGHTS OF PRESCRIBING INFORMATION Venous Thromboembolism ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKINIST® is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved ... View Doc

SPECIALTY GUIDELINE MANAGEMENT - Caresource.com
Zelboraf is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Zelboraf [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2016. ... Read Document

HIGHLIGHTS OF PRESCRIBING INFORMATION Cardiomyopathy: Assess ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma TAFINLAR® is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration ... Read More

ZELBORAF RATIONALE FOR INCLUSION IN PA PROGRAM
Zelboraf is an orally-administered drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, non-small cell lung cancer, hairy cell leukemia, and Erdheim-Chester disease or Langerhans cell histiocytosis. ... Document Retrieval

Information Meeting On ZELBORAF And Cobas BRAF V600 Mutation Test
Patients receiving ZELBORAF should be conducted until data for a set number of patients are collected in order to identify the background characteristics of patients using ZELBORAF, collect early data on the safety and efficacy of ZELBORAF, and take necessary measures for appropriate use of ZELBORAF. Package Insert: Dec. 2014 (Version 1) ... Retrieve Content

Reference ID: 4177271 - Genentech
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Unresectable or Metastatic Melanoma ZELBORAF® is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ... Document Retrieval

SPECIALTY GUIDELINE MANAGEMENT - Provider.carefirst.com
Zelboraf SGM P2018 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of ... Content Retrieval

Ipilimumab - Wikipedia
Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. ... Read Article

5.21.14 Zelboraf Vemurafenib 3 18 16 EA
Zelboraf [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2015 Policy History Date Action February 2012 New Policy March 2013 Annual editorial review and reference update Removal of renewal requirements of no disease progression. ... View Full Source

Reference ID: 3845167 - Food And Drug Administration
Effect of Strong or Moderate CYP3A4 Inhibitors on Cobimetinib 7.2 . Effect of Strong or Moderate CYP3A Inducers on Cobimetinib . 8 USE IN SPECIFIC POPULATIONS . 8.1 Pregnancy . 8.2 Lactation . 8.3 Females and Males of Reproductive Potential . 8.4 Pediatric Use . ... Doc Retrieval

2 FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . MEKINIST™ as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved ... Access Content

Reference ID: 3804690 - Food And Drug Administration
The recommended dose of ZELBORAF is 960 mg (four 240 mg tablets) orally every 12 hours with or without a meal. A missed dose can be taken up to 4 hours prior to the next dose. Treat patients with ZELBORAF until disease progression or unacceptable toxicity occurs. ... Document Retrieval

SPRYCEL (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ... Retrieve Full Source

Antineoplastic Agents - BMC HealthNet Plan
Keytruda® (package insert). Whitehouse (NJ): Merck; Jan 2015. + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. ... Fetch Document

1 INDICATIONS AND USAGE ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. ... Retrieve Content

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TAFINLAR with trametinibsafely and effectively. ... Get Document

Reference ID: 3001518 - Food And Drug Administration
ZELBORAF clinical studies included age (≥65 years), prior skin cancer, and chronic sun exposure. In the clinical trials, cases of cuSCC were managed with excision, and patients were able to continue treatment without dose adjustment. ... Read More

HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. 1.2 Non-Small Cell Lung Cancer ... Fetch Full Source

SPECIALTY GUIDELINE MANAGEMENT - Caremark.com
Zelboraf is used as a single agent or in combination with cobimetinib c. Member has not received a prior BRAF-inhibitor therapy. 2. Authorization for 12 months may be granted for treatment of brain metastases when all of the following Zelboraf [package insert]. South San Francisco, CA ... Document Viewer

Last Review Status/Date - Media.fepblue.org
Zelboraf is an orally-administered drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, non-small cell lung cancer, hairy cell leukemia, and Erdheim-Chester disease or Langerhans cell histiocytosis. ... Access Content